NCT07001995View on ClinicalTrials.gov

Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 30, 2027

Study Completion Date

October 30, 2028

Conditions
Small Cell Lung CancerNon Small Cell Lung Cancer
Interventions
DRUG

limertinib

limertinib 80 mg

DRUG

etoposide and carboplatin

etoposide 100 mg/m² IV D1-3 + carboplatin AUC 5-6 IV

Trial Locations (1)

410013

Yongchang Zhang, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER